Systemic Stem Cell Dosing for Heart Failure
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for heart failure, particularly ischemic heart failure, face limitations due to invasive delivery methods that are costly, labor-intensive, and not suitable for repeated administrations, with transplanted cells often disappearing rapidly, limiting their efficacy.
Innovation Solution
Systemic delivery of multiple doses of mesenchymal stem cells via intravenous administration, targeting the spleen and other immune tissues to reduce systemic inflammation and improve heart function, using cells derived from umbilical cord or bone marrow, with dosing intervals ranging from one day to one year and cell concentrations between 0.5 to 5 million cells per kg.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If local delivery methods (intracoronary, transendocardial, or transepicardial) are used to deliver stem cells to the myocardium, then the cells can directly reach the heart tissue, but the procedure becomes invasive, costly, labor-intensive, and not suitable for repeated administrations
Solution Approach 1:
Instead of delivering cells directly to the heart through invasive local methods, the patent inverts the approach by delivering cells systemically through intravenous injection. The cells are administered through the bloodstream and naturally homed to the heart tissue, converting an invasive local delivery problem into a simple systemic delivery solution that can be repeated easily
Solution Approach 2:
The patent uses the bloodstream as an intermediary medium to transport stem cells from the injection site to the heart tissue. This intermediary system (circulatory system) eliminates the need for direct invasive access to the myocardium while still achieving effective cell delivery to the target tissue
2Ease of manufacture
If single dose local delivery is used, then the procedure is simpler, but the transplanted cells disappear rapidly limiting therapeutic efficacy
Solution Approach 1:
The patent implements periodic action by administering multiple doses of stem cells at scheduled intervals (e.g., weekly or monthly injections). This periodic systemic delivery ensures continuous replenishment of cells in the heart tissue, overcoming the rapid disappearance problem of single-dose therapy while maintaining treatment simplicity through easy intravenous administration
Solution Approach 2:
The patent achieves continuity of useful action through repeated systemic dosing, ensuring a continuous supply of stem cells to the heart tissue. This continuous therapeutic action maintains effective cell presence in the myocardium over time, unlike single-dose approaches where cell presence is transient
Data Source
AI summary
Methods to treat heart failure and reduce systemic inflammation are provided. The methods include systemically delivering to a subject at least two doses, for example 2-10 doses, of mesenchymal stem cells, wherein the at least two doses are separated by an interval of time, such as from 1 day to 1 year.